Drugs / Interferon-α
Interferon-α
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT00470093 | Oct 2007 → Jan 2010 | plasma cell myeloma | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Terminated | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02470468 | Dec 2014 → Jan 2018 | non-small cell lung carcinoma | SOTIO a.s. | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT04534634 | Apr 2019 → Jul 2023 | B-cell acute lymphoblastic leukemia | The First Affiliated Hospital of Soochow University | Unknown | No outcome recorded |
| Phase 2 | NCT01171209 | Jul 2010 → Jun 2011 | multiple sclerosis | Melinda Magyari | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT04320238 | Jan → May 2020 | COVID-19 | Shanghai Jiao Tong University School of Medicine | Unknown | No outcome recorded |
Also used as a comparator or background therapy in 3 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00277017 Background | Sep 2000 → Aug 2005 | cancer, kidney disorder | New Mexico Cancer Research Alliance | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT05783206 Background | Feb 2022 → Jul 2023 | COVID-19 | National Research Center - Institute of Immunology Federal Medical-Biological Agency of Russia | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT00397345 Background | Sep 2006 → Dec 2009 | clear cell renal carcinoma | Oxford BioMedica | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Interferon-α | “DCVAC +/- immune enhancers (Interferon-α and Hydroxychloroquine) add on to SOC (Carboplatin, Paclitaxel): until progression or intolerance or death” NCT02470468 ↗6“Adults: 14 daily intramuscular injections 300 million IU of Interferon-α for a 28-day cycle.” NCT04534634 ↗ “interferon-α, intranasal forms (Grippferon®),spray - in accordance with the instructions.” NCT05783206 ↗ “Interferon-α, given subcutaneously on Day 1, 3 and 5 of every week for 4 weeks.” NCT00277017 ↗ “subcutaneous low dose IL-2, interferon-α or sunitinib” NCT00397345 ↗ |
| Known as | Grippferon | “interferon-α, intranasal forms (Grippferon®),spray - in accordance with the instructions.” NCT05783206 ↗ |
| Known as | IFN-α | “The primary objective of this study is to investigate the in vivo biological response to interferon-alpha (IFN-α) in MS patients, who have developed neutralising antibodies...” PMID 25877635 ↗ Dec 2012 |
| Known as | recombinant human interferon Alpha-1b | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04320238 ↗ |
| Modality | Protein / enzyme biologic | “recombinant interferon-α” NCT00470093 ↗ |
| Route | Subcutaneous | “Interferon-α, given subcutaneously on Day 1, 3 and 5 of every week for 4 weeks.” NCT00277017 ↗ |